Open Access Articles- Top Results for CB-13


Systematic (IUPAC) name
Clinical data
432047-72-8 7pxY
PubChem CID 9799417
Chemical data
Formula C26H24O2
368.467 g/mol
 14pxY (what is this?)  (verify)

CB-13 (CRA13, SAB-378)[1] is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,[2] and has progressed to preliminary human trials.[3]

See also


  1. Cluny, N. L.; Keenan, C. M.; Duncan, M.; Fox, A.; Lutz, B.; Sharkey, K. A. (2010). "Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice". Journal of Pharmacology and Experimental Therapeutics 334 (3): 973–80. PMID 20571060. doi:10.1124/jpet.110.169946.  edit
  2. doi:10.1021/jm070317a
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand
  3. Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (April 2009). "Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety". Drug Metabolism and Disposition: the Biological Fate of Chemicals 37 (4): 827–33. PMID 19144772. doi:10.1124/dmd.108.024000. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.